The Supreme Court declined to get involved in a patent dispute among Amgen, Aventis Pharmaceuticals and Shire Genetic Therapies concerning Amgen's Epogen anemia drug. Amgen had appealed to the high court a circuit court decision, which ruled only two of the Amgen patents were valid and reversed a district court's decision in support of two others.

Related Summaries